adefovir

(redirected from Adefovir dipivoxil)
Also found in: Medical.
Related to Adefovir dipivoxil: Entecavir, Tenofovir
Translations

adefovir

n adefovir m
References in periodicals archive ?
2, ATC code: J05AF08, Generic Name: Adefovir dipivoxil, Pharmaceutical form: Tablets Strength: 10 mg, Unit Value: 10 mg, Quantity in units 4 185 thereof.
More recently, the nucleotide analogue adefovir dipivoxil, the prodrug of adefovir, was licensed for treatment of chronic hepatitis B10.
Adefovir dipivoxil is active against HBV but not against HIV at the 10 mg dose; however, there is a theoretical risk of development of HIV resistance, as it has anti-HIV activity at higher doses and is related to tenofovir.
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
The rate of resistance after 4 years on adefovir dipivoxil (Hepsera) monotherapy is 18%.
Adefovir dipivoxil (Hepsera), a nucleotide analogue approved in 2002, is active against lamivudine-resistant virus, but can cause nephrotoxicity.
Important clinical information, including the approval of adefovir dipivoxil for treatment and clinical trials on its efficacy, are not included.
Treatment with adefovir dipivoxil (Hepsera, Gilead Sciences) both prior to and following liver transplantation in patients with lamivudine-resistant chronic hepatitis B (HBV) infection, significantly improves virologic, biochemical, and clinical parameters, results of an open-label, compassionate use study indicate.
Treatment with interferon, pegylated-interferon, lamivudine, adefovir dipivoxil and entecavir is available to help people with chronic hepatitis B.
But Federal agencies like the Food and Drug Administration (FDA) have also had their swings, from the approval of nelfinavir without a public meeting to the rejection of adefovir dipivoxil much to the disappointment of many, especially its developer.
Co-administration with other products Complera should not be administered concurrently with other medicinal products containing any of the same active components, emtricitabine, rilpivirine, or tenofovir disoproxil fumarate (Emtriva, Edurant, Viread, Truvada, Atripla), with medicinal products containing lamivudine (Epivir, Epivir-HBV, Epzicom, Combivir, Trizivir), or with adefovir dipivoxil (Hepsera).
In 2005, adefovir dipivoxil made by GSK was first approved to enter China under the trade name of Hepsera.